Literature DB >> 27865774

A systems toxicology approach for comparative assessment: Biological impact of an aerosol from a candidate modified-risk tobacco product and cigarette smoke on human organotypic bronchial epithelial cultures.

Anita R Iskandar1, Carole Mathis2, Walter K Schlage3, Stefan Frentzel4, Patrice Leroy5, Yang Xiang6, Alain Sewer7, Shoaib Majeed8, Laura Ortega-Torres9, Stephanie Johne10, Emmanuel Guedj11, Keyur Trivedi12, Gilles Kratzer13, Celine Merg14, Ashraf Elamin15, Florian Martin16, Nikolai V Ivanov17, Manuel C Peitsch18, Julia Hoeng19.   

Abstract

This study reports a comparative assessment of the biological impact of a heated tobacco aerosol from the tobacco heating system (THS) 2.2 and smoke from a combustible 3R4F cigarette. Human organotypic bronchial epithelial cultures were exposed to an aerosol from THS2.2 (a candidate modified-risk tobacco product) or 3R4F smoke at similar nicotine concentrations. A systems toxicology approach was applied to enable a comprehensive exposure impact assessment. Culture histology, cytotoxicity, secreted pro-inflammatory mediators, ciliary beating, and genome-wide mRNA/miRNA profiles were assessed at various time points post-exposure. Series of experimental repetitions were conducted to increase the robustness of the assessment. At similar nicotine concentrations, THS2.2 aerosol elicited lower cytotoxicity compared with 3R4F smoke. No morphological change was observed following exposure to THS2.2 aerosol, even at nicotine concentration three times that of 3R4F smoke. Lower levels of secreted mediators and fewer miRNA alterations were observed following exposure to THS2.2 aerosol than following 3R4F smoke. Based on the computational analysis of the gene expression changes, 3R4F (0.13 mg nicotine/L) elicited the highest biological impact (100%) in the context of Cell Fate, Cell Proliferation, Cell Stress, and Inflammatory Network Models at 4 h post-exposure. Whereas, the corresponding impact of THS2.2 (0.14 mg nicotine/L) was 7.6%.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Reconstituted epithelium; air-liquid interface; causal biological network modelling; product testing; transcriptomics

Mesh:

Substances:

Year:  2016        PMID: 27865774     DOI: 10.1016/j.tiv.2016.11.009

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  15 in total

1.  Analysis of the risk factors of postoperative cardiopulmonary complications and ability to predicate the risk in patients after lung cancer surgery.

Authors:  Yue Li; Yin-Lu Ma; Yong-Yin Gao; Dan-Dan Wang; Qing Chen
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  Acute Effects of Heated Tobacco Product (IQOS) Aerosol Inhalation on Lung Tissue Damage and Inflammatory Changes in the Lungs.

Authors:  Tariq A Bhat; Suresh G Kalathil; Noel Leigh; Thivanka Muthumalage; Irfan Rahman; Maciej L Goniewicz; Yasmin M Thanavala
Journal:  Nicotine Tob Res       Date:  2021-06-08       Impact factor: 4.244

3.  Knowledge and Attitudes Among Medical Students Toward the Clinical Usage of e-Cigarettes: A Cross-Sectional Study in a University Hospital in Saudi Arabia.

Authors:  Sami H Alzahrani; Rawan A Alghamdi; Ahmed Mabruk Almutairi; Ali Ahmed Alghamdi; Abdullah Abdulwahab Aljuhani; Abdulrahman Hamed ALbalawi
Journal:  Risk Manag Healthc Policy       Date:  2021-05-13

4.  In vitro RNA-seq-based toxicogenomics assessment shows reduced biological effect of tobacco heating products when compared to cigarette smoke.

Authors:  Linsey E Haswell; Sarah Corke; Ivan Verrastro; Andrew Baxter; Anisha Banerjee; Jason Adamson; Tomasz Jaunky; Christopher Proctor; Marianna Gaça; Emmanuel Minet
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

5.  Reduced biological effect of e-cigarette aerosol compared to cigarette smoke evaluated in vitro using normalized nicotine dose and RNA-seq-based toxicogenomics.

Authors:  Linsey E Haswell; Andrew Baxter; Anisha Banerjee; Ivan Verrastro; Jessica Mushonganono; Jason Adamson; David Thorne; Marianna Gaça; Emmanuel Minet
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

6.  Systems toxicology meta-analysis of in vitro assessment studies: biological impact of a candidate modified-risk tobacco product aerosol compared with cigarette smoke on human organotypic cultures of the aerodigestive tract.

Authors:  A R Iskandar; B Titz; A Sewer; P Leroy; T Schneider; F Zanetti; C Mathis; A Elamin; S Frentzel; W K Schlage; F Martin; N V Ivanov; M C Peitsch; J Hoeng
Journal:  Toxicol Res (Camb)       Date:  2017-05-29       Impact factor: 3.524

7.  Comparative effects of a candidate modified-risk tobacco product Aerosol and cigarette smoke on human organotypic small airway cultures: a systems toxicology approach.

Authors:  Anita R Iskandar; Yannick Martinez; Florian Martin; Walter K Schlage; Patrice Leroy; Alain Sewer; Laura Ortega Torres; Shoaib Majeed; Celine Merg; Keyur Trivedi; Emmanuel Guedj; Stefan Frentzel; Carole Mathis; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng
Journal:  Toxicol Res (Camb)       Date:  2017-09-28       Impact factor: 3.524

8.  Impact of sample preparation upon intracellular metabolite measurements in 3D cell culture systems.

Authors:  Caroline Mathon; David Bovard; Quentin Dutertre; Sandra Sendyk; Mark Bentley; Julia Hoeng; Arno Knorr
Journal:  Metabolomics       Date:  2019-06-12       Impact factor: 4.290

9.  Multi-endpoint analysis of human 3D airway epithelium following repeated exposure to whole electronic vapor product aerosol or cigarette smoke.

Authors:  Lukasz Czekala; Roman Wieczorek; Liam Simms; Fan Yu; Jessica Budde; Edgar Trelles Sticken; Kathryn Rudd; Thomas Verron; Oleg Brinster; Matthew Stevenson; Tanvir Walele
Journal:  Curr Res Toxicol       Date:  2021-02-20

10.  Ga-68 EDTA aerosols in evaluation of inhaled-particle deposition and clearance of obstructive pulmonary diseases: A pilot prospective study compared with Galligas.

Authors:  Shao-Ting Wang; Cheng Bao; Qingxing Liu; Tengyue Zhang; Yanli Yang; Xinlun Tian; Zhaohui Zhu; Kai-Feng Xu
Journal:  Eur J Clin Invest       Date:  2021-06-02       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.